Regulatory Action
Optival Health Solutions, a subsidiary of MedPlus Health Services Ltd, has received suspension orders for drug licenses at two of its Telangana outlets. The suspensions were issued on September 8, 2025, by the Assistant Director of Drugs Control Administration, Secunderabad, under provisions of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
Stores Affected
- West Marredpally Circle store: 1-day suspension
- Vijayapuri Colony South Lalaguda Road store: 4-day suspension
Financial Impact
The company estimates a combined revenue loss of ₹1.5 lakh from these suspensions:
| Store Location | Estimated Loss |
| West Marredpally Circle | ₹0.57 lakh |
| Vijayapuri Colony South Lalaguda Road | ₹0.93 lakh |
Compliance & Disclosure
- The disclosure was made in line with SEBI (LODR) Regulations, 2015 and relevant SEBI circulars.
- MedPlus confirmed that the details will also be available on its website and on stock exchange portals (BSE and NSE).
Industry Context
While the financial hit is marginal, the suspensions highlight the regulatory compliance challenges faced by retail pharmacy chains in India. MedPlus reiterated its commitment to transparency and adherence to licensing norms.
Summary
- Optival Health Solutions, MedPlus’ subsidiary, faces temporary drug license suspensions at two Telangana stores.
- The impact: 1-day and 4-day suspensions, with an estimated revenue loss of ₹1.5 lakh total.
- The action was taken under the Drugs and Cosmetics Act & Rules, reinforcing the need for strict compliance in India’s pharmacy retail sector.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.